Pharma Focus Asia
MasterControl - Avoid Falling Behind the Pharma Market

Boehringer Ingelheim Launches New SGLT-2 Inhibitor Esgliteo

Tuesday, July 18, 2023

Boehringer Ingelheim has launched Esgliteo (empagliflozin/linagliptin), a compound therapy of the SGLT-2 inhibitor Jardiance (empagliflozin) and the DPP-4 inhibitor Trajenta (linagliptin).

Esgliteo is its smaller tablet size, measuring approximately 8.1 millimetres. This size is intended to enhance convenience for patients who struggle with swallowing larger pills. Additionally, Esgliteo offers two dosage options to cater to patients in need of additional glycaemic control: 10 mg of empagliflozin combined with 5 mg of linagliptin, or 25 mg of empagliflozin with 5 mg of linagliptin.

Esgliteo brings several benefits as a combination therapy. Firstly, it delivers a superior glucose-lowering effect compared to either medication used alone. In the EMPA-REG OUTCOME study, empagliflozin, the SGLT-2 inhibitor component, demonstrated a significant cardiovascular benefit by reducing the risk of major cardiovascular events (cardiovascular-related death, nonfatal myocardial infarction, or nonfatal stroke) by 14% compared to a placebo.

Esgliteo harnesses the complementary mechanisms of SGLT-2 and DPP-4 inhibitors to achieve enhanced glucose control. In a phase 3 study, Esgliteo exhibited improved glycemic control at week 24 when compared to using empagliflozin or linagliptin alone as monotherapies.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Increasing the likelihood of your drug approvalMasterControl - Manufacturing demoMasterControl - QMS demoBora Pharmaceuticals - Free WhitepaperThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® productsMedical Fair Thailand 20235th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023
MasterControl - 6 Essential Features in an eQMS